News headlines about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.6265231176175 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
MDGL has been the subject of several recent research reports. Roth Capital initiated coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $62.00 target price for the company. Evercore ISI initiated coverage on shares of Madrigal Pharmaceuticals in a research report on Friday, September 22nd. They set an “outperform” rating and a $65.00 target price for the company. JMP Securities boosted their target price on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an “outperform” rating in a research report on Friday, October 13th. Finally, HC Wainwright initiated coverage on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 29th. They set a “buy” rating and a $54.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $66.00.
Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) traded down $1.74 during mid-day trading on Monday, reaching $47.98. 99,043 shares of the company’s stock were exchanged, compared to its average volume of 43,891. Madrigal Pharmaceuticals has a twelve month low of $13.09 and a twelve month high of $53.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.11. equities analysts predict that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Madrigal Pharmaceuticals (MDGL) Receives Daily Media Impact Rating of 0.19” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/04/madrigal-pharmaceuticals-mdgl-receiving-somewhat-positive-press-coverage-study-shows.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.